Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2005 9
2006 7
2007 11
2008 14
2009 14
2010 22
2011 32
2012 45
2013 37
2014 35
2015 35
2016 44
2017 44
2018 39
2019 35
2020 44
2021 47
2022 29
2023 26
2024 23
2025 48
2026 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

581 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen AØ, Zeeman VA, Johannsen CF, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jørgensen NR, Bergmann ML, Enghusen Poulsen H, Becker U, Holst JJ, Benveniste H, Volkow ND, Vollstädt-Klein S, Miskowiak KW, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Klausen MK, et al. JCI Insight. 2022 Oct 10;7(19):e159863. doi: 10.1172/jci.insight.159863. JCI Insight. 2022. PMID: 36066977 Free PMC article. Clinical Trial.
The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its efficacy in patients with AUD is unknown.MethodsIn a randomized, double-blinded, placebo-controlled clinical trial, treatment-seeking AUD pa …
The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its …
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Holman RR, et al. N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14. N Engl J Med. 2017. PMID: 28910237 Free PMC article. Clinical Trial.
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcut …
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes …
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Athauda D, et al. Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3. Lancet. 2017. PMID: 28781108 Free PMC article. Clinical Trial.
BACKGROUND: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. ...FINDINGS: Between June 18, 2014, and March 13, 2015, 62 patients were enrolled and randomly assigned, 32 to exenatide …
BACKGROUND: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parki …
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. Ahmann AJ, et al. Diabetes Care. 2018 Feb;41(2):258-266. doi: 10.2337/dc17-0417. Epub 2017 Dec 15. Diabetes Care. 2018. PMID: 29246950 Clinical Trial.

Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD -3.78 kg [95% CI -4.58, -2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA(1c) <7.0% (<53 mmol/mol) versus tho

…
Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD -3.78 kg [95% CI -4.5 …
A Pilot Study of Exenatide Actions in Alzheimer's Disease.
Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D. Mullins RJ, et al. Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950. Curr Alzheimer Res. 2019. PMID: 31518224 Free PMC article. Clinical Trial.
BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease-modifying in Alzheimer's Disease (AD). ...However, the analysis of secondary outcomes show …
BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treatin …
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J, Duncan G, Power K, Gallen S, Kerr J, Chaudhuri KR, Batzu L, Rota S, Jabbari E, Morris H, Limousin P, Greig N, Li Y, Libri V, Gandhi S, Athauda D, Chowdhury K, Foltynie T. Vijiaratnam N, et al. Lancet. 2025 Feb 22;405(10479):627-636. doi: 10.1016/S0140-6736(24)02808-3. Epub 2025 Feb 4. Lancet. 2025. PMID: 39919773 Free article. Clinical Trial.
At 96 weeks, MDS-UPDRS III OFF-medication scores had increased (worsened) by a mean of 5.7 points (SD 11.2) in the exenatide group, and by 4.5 points (SD 11.4) points in the placebo group (adjusted coefficient for the effect of exenatide 0.92 [95% CI -1.56 to 3.39]; …
At 96 weeks, MDS-UPDRS III OFF-medication scores had increased (worsened) by a mean of 5.7 points (SD 11.2) in the exenatide group, a …
The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.
Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, Greig NH, Li Y, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ. Mitchell JL, et al. Brain. 2023 May 2;146(5):1821-1830. doi: 10.1093/brain/awad003. Brain. 2023. PMID: 36907221 Free PMC article. Clinical Trial.
Here, we translate these findings into patients by conducting a randomized, placebo-controlled, double-blind trial to assess the effect of exenatide, a GLP-1 receptor agonist, on intracranial pressure in idiopathic intracranial hypertension. ...The trial enrolled adult wom …
Here, we translate these findings into patients by conducting a randomized, placebo-controlled, double-blind trial to assess the effect of …
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Elkind-Hirsch KE, et al. J Clin Endocrinol Metab. 2021 Sep 27;106(10):3019-3033. doi: 10.1210/clinem/dgab408. J Clin Endocrinol Metab. 2021. PMID: 34097062 Free article. Clinical Trial.
OBJECTIVE: The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered (EQW/DAPA), DAPA/extended-release (ER) metformin (DAPA/MET), and phentermine topiramate extended release (PHEN/TPM) on metabolic parameters, body composition, and sex h …
OBJECTIVE: The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered (EQW/DAPA), DAPA/extended-re …
A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.
Patino LR, Strawn JR, Adler CM, Blom TJ, Welge JA, DelBello MP. Patino LR, et al. J Affect Disord. 2025 Aug 1;382:116-122. doi: 10.1016/j.jad.2025.04.046. Epub 2025 Apr 7. J Affect Disord. 2025. PMID: 40203970 Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine. METHODS: Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks. ...CONCLUSIONS: Exe …
OBJECTIVE: To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine. METHODS: Adults wi …
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Neves JS, Leite AR, Mentz RJ, Holman RR, Zannad F, Butler J, Packer M, Ferreira JP. Neves JS, et al. Eur J Heart Fail. 2025 Mar;27(3):540-551. doi: 10.1002/ejhf.3478. Epub 2024 Oct 9. Eur J Heart Fail. 2025. PMID: 39381950 Free article. Clinical Trial.
However, previous studies suggest the effects on heart failure outcomes vary according to left ventricular ejection fraction (LVEF). We aimed to evaluate the effects of exenatide on cardiovascular events according to LVEF in people with T2D. METHODS AND RESULTS: Post-hoc a …
However, previous studies suggest the effects on heart failure outcomes vary according to left ventricular ejection fraction (LVEF). We aime …
581 results